Advance Search
ZHU Yuqin, GUO Kai. Research progress of cardiovascular benefits patients treated by gucagon like peptide-1 receptor agonists[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 107-110. DOI: 10.7619/jcmp.20200711
Citation: ZHU Yuqin, GUO Kai. Research progress of cardiovascular benefits patients treated by gucagon like peptide-1 receptor agonists[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 107-110. DOI: 10.7619/jcmp.20200711
shu

Research progress of cardiovascular benefits patients treated by gucagon like peptide-1 receptor agonists

  • 1.

    Department of Emergency, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090

  • 2.

    Department of Endocrinology and Metabolism, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090

More Information
  • Received Date: November 22, 2020
  • Available Online: March 03, 2021
  • Published Date: March 03, 2021
    Graphical Abstract
    • Abstract
  • Diabetes is a major risk factor for cardiovascular disease (CVD), and cardiovascular related complications are the leading causes of death in patients with type 2 diabetes. Gglucagon-like peptid-1 receptor agonist (GLP-1 RA) as a new type of drug for the treatment of diabetes, can not only protect the myocardium, but also play a protective role in the cardiovascular system through relevant mechanisms. GLP-1 RA has different pharmacodynamic properties. In this review, the results of cardiovascular trials on GLP-1RA in recent years were reviewed, and the potential differences and potency of GLP-1 RA in the cardiovascular system are further discussed.
    • FullText(HTML)
    • References (32)
  • [1]
    MEIER J J, GETHMANN A, GÖTZE O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans[J]. Diabetologia, 2006, 49(3): 452-458. doi: 10.1007/s00125-005-0126-y
    [2]
    ZANDER M, MADSBAD S, MADSEN J L, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study[J]. Lancet, 2002, 359(9309): 824-830. doi: 10.1016/S0140-6736(02)07952-7
    [3]
    缪培智. 达格列净在心血管疾病中的作用研究进展[J]. 内科理论与实践, 2020, 15(2): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-NKLL202002003.htm
    [4]
    TANCREDI M, ROSENGREN A, SVENSSON A M, et al. Excess mortality among persons with type 2 diabetes[J]. N Engl J Med, 2015, 373(18): 1720-1732. doi: 10.1056/NEJMoa1504347
    [5]
    TENTOLOURIS A, ELEFTHERIADOU I, ATHANASAKIS K, et al. Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population[J]. Hellenic J Cardiol, 2020, 61(1): 15-22. doi: 10.1016/j.hjc.2018.04.008
    [6]
    SKLIROS N P, VLACHOPOULOS C, TOUSOULIS D. Treatment of diabetes: Crossing to the other side[J]. Hellenic J Cardiol, 2016, 57(5): 304-310. doi: 10.1016/j.hjc.2016.07.002
    [7]
    TSIOUFIS C, ANDRIKOU E, THOMOPOULOS C, et al. Oral glucose-lowering drugs and cardiovascular outcomes: from the negative RECORD and ACCORD to neutral TECOS and promising EMPA-REG[J]. Curr Vasc Pharmacol, 2017, 15(5): 457-468. http://www.ncbi.nlm.nih.gov/pubmed/27928947
    [8]
    MARSO S P, DANIELS G H, BROWN-FRANDSEN K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322. doi: 10.1056/NEJMoa1603827
    [9]
    PFEFFER M A, CLAGGETT B, DIAZ R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med, 2015, 373(23): 2247-2257. doi: 10.1056/NEJMoa1509225
    [10]
    MARSO S P, BAIN S C, CONSOLI A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19): 1834-1844. doi: 10.1056/NEJMoa1607141
    [11]
    HOLMAN R R, BETHEL M A, MENTZ R J, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(13): 1228-1239. doi: 10.1056/NEJMoa1612917
    [12]
    HERNANDEZ A F, GREEN J B, JANMOHAMED S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2018, 392(10157): 1519-1529. doi: 10.1016/S0140-6736(18)32261-X
    [13]
    GERSTEIN H C, COLHOUN H M, DAGENAIS G R, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2019, 394(10193): 121-130. doi: 10.1016/S0140-6736(19)31149-3
    [14]
    SCHNELL O, RYDÉN L, STANDL E, et al. Updates on cardiovascular outcome trials in diabetes[J]. Cardiovasc Diabetol, 2017, 16(1): 128. doi: 10.1186/s12933-017-0610-y
    [15]
    LIM S, KIM K M, NAUCK M A. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns[J]. Trends Endocrinol Metab, 2018, 29(4): 238-248. doi: 10.1016/j.tem.2018.01.011
    [16]
    JIA X, ALAM M, YE Y, et al. GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials[J]. Cardiovasc Drugs Ther, 2018, 32(1): 65-72. doi: 10.1007/s10557-018-6773-2
    [17]
    DEFRONZO R A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009[J]. Diabetologia, 2010, 53(7): 1270-1287. doi: 10.1007/s00125-010-1684-1
    [18]
    BISTOLA V, LAMBADIARI V, DIMITRIADIS G, et al. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors[J]. Heart Fail Rev, 2018, 23(3): 377-388. doi: 10.1007/s10741-018-9674-3
    [19]
    SUN F, WU S, GUO S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis[J]. Diabetes Res Clin Pract, 2015, 110(1): 26-37. doi: 10.1016/j.diabres.2015.07.015
    [20]
    LI D, XU X, ZHANG Y, et al. Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes[J]. Diabetes Res Clin Pract, 2015, 110(2): 224-228. doi: 10.1016/j.diabres.2015.05.051
    [21]
    熊周怡, 熊斌, 吴建能. 胰升血糖素样肽1对晚期氧化蛋白产物诱导的心肌细胞凋亡保护作用的研究[J]. 中国糖尿病杂志, 2017, 25(6): 558-562. doi: 10.3969/j.issn.1006-6187.2017.06.016
    [22]
    YOUNCE C W, BURMEISTER M A, Ayala J E. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic Reticulum stress and activation of SERCA2a[J]. Am J Physiol Cell Physiol, 2013, 304(6): C508-C518. doi: 10.1152/ajpcell.00248.2012
    [23]
    刘晶晶, 魏丽, 王建波. GLP-1受体激动剂对2型糖尿病患者血管病变影响的研究进展[J]. 中国医药导报, 2017, 14(18): 38-41. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201718010.htm
    [24]
    WANG M, KIM S H, MONTICONE R E, et al. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis[J]. Hypertension, 2015, 65(4): 698-703. doi: 10.1161/HYPERTENSIONAHA.114.03618
    [25]
    NAGAYAMA K, KYOTANI Y, ZHAO J, et al. Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin Ⅱ via the inhibition of ERK1/2 and JNK signaling pathways[J]. PLoS One, 2015, 10(9): e0137960. doi: 10.1371/journal.pone.0137960
    [26]
    SCHEEN A J, ESSER N, PAQUOT N. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control[J]. Diabetes Metab, 2015, 41(3): 183-194. doi: 10.1016/j.diabet.2015.02.003
    [27]
    NYSTRÖM T, GUTNIAK M K, ZHANG Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease[J]. Am J Physiol Endocrinol Metab, 2004, 287(6): E1209-E1215. doi: 10.1152/ajpendo.00237.2004
    [28]
    李晶晶, 孙立娟. 胰高血糖素样肽-1受体激动剂对2型糖尿病合并冠心病患者心功能的影响[J]. 中国实验诊断学, 2020, 24(3): 450-451. doi: 10.3969/j.issn.1007-4287.2020.03.024
    [29]
    MUNAF M, PELLICORI P, ALLGAR V, et al. A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure[J]. Int J Pept, 2012, 2012: 249827. http://www.ncbi.nlm.nih.gov/pubmed/22811735
    [30]
    MARGULIES K B, HERNANDEZ A F, REDFIELD M M, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2016, 316(5): 500-508. doi: 10.1001/jama.2016.10260
    [31]
    UCCELLATORE A, GENOVESE S, DICEMBRINI I, et al. Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists[J]. Diabetes Ther, 2015, 6(3): 239-256. doi: 10.1007/s13300-015-0127-x
    [32]
    HTIKE Z Z, ZACCARDI F, PAPAMARGARITIS D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis[J]. Diabetes Obes Metab, 2017, 19(4): 524-536. doi: 10.1111/dom.12849
    • Related Articles

  • Cited by

    Periodical cited type(9)

    1. 任杰. 戈舍瑞林联合腹腔镜卵巢囊肿剥除术治疗卵巢巧克力囊肿的回顾性研究. 临床医学. 2025(01): 42-44 .
    2. 张鹏玲，黄建璇，蔡楠，孙军萍. 凝血指标、生育指数评分与卵巢巧克力囊肿不孕术后妊娠的相关性分析. 实用医院临床杂志. 2025(02): 155-159 .
    3. 冯钰玲，余姝婷. GnRH-a联合地诺孕素在卵巢巧克力囊肿术后维持治疗中的应用效果分析. 延边大学医学学报. 2025(02): 88-91 .
    4. 章斌斌. 地诺孕素联合醋酸亮丙瑞林缓释微球应用于卵巢子宫内膜异位囊肿术后治疗的临床效果. 临床合理用药. 2024(25): 16-18+22 .
    5. 车艳美. 卵巢巧克力囊肿术后患者使用地诺孕素的临床效果研究. 实用妇科内分泌电子杂志. 2023(01): 17-19 .
    6. 侯宇飞，卜范玉. 地诺孕素不同给药时间对经腹腔镜术治疗卵巢巧克力囊肿的疗效及复发情况的影响. 中国药物经济学. 2023(10): 61-65 .
    7. 吴珊. 腹腔镜卵巢囊肿剥除术结合醋酸亮丙瑞林治疗卵巢巧克力囊肿患者的临床疗效分析. 现代诊断与治疗. 2023(16): 2458-2460 .
    8. 杨姣妹. 经腹部与经阴道超声联合检查在卵巢巧克力囊肿与盆腔炎性囊肿中的鉴别诊断价值分析. 影像研究与医学应用. 2023(21): 152-154 .
    9. 刘杨雪珂，刘青，许文文. 超声介入治疗在卵巢巧克力囊肿患者中的应用价值. 透析与人工器官. 2023(04): 9-12 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (439) PDF downloads (24) Cited by(9)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return